In lung and pancreatic cancers, SMYD3 is localized in the cytoplasm, where it enhances RAS/ERK signaling by mediating the methylation of MAP3K2 kinase and preventing its interaction with the PP2A phosphatase complex [59]. This evidence concerns the gene PTPA and familial pancreatic carcinoma.